不受控制的炎症导致组织的非特异性破坏和重塑，并且可能导致许多人类病理，包括肺疾病。激发炎症解决被认为是一种重要的过程，可以保护免受慢性炎症性疾病的进展。通过与特定受体结合，由必需的ω-3多不饱和脂肪酸生成的解决素已被证明是炎症中的信号分子，具有重要的促解决和抗炎能力。通过调节中性粒细胞迁移、巨噬细胞吞噬功能和促炎介质的存在，解决素可以减少炎症病变。这些促解决介质的发现已导致了药物研究的转变，从抑制促炎分子转向研究促进解决的化合物以治疗炎症。对炎症解决的探索还提供了进一步了解肺部疾病的病理生理的机会。解决的改变现在与哮喘、慢性阻塞性肺疾病、囊性纤维化、急性呼吸窘迫综合征、癌症和COVID-19的发展和加重都有关联。这些发现导致了新型的解决为基础的治疗药物的设计和测试的出现，以治疗这些疾病。因此，本文回顾了解决素的产生和机制作用，并调查了它们在几种可能受益于解决为基础药物的肺部疾病中的作用和治疗潜力。Copyright © 2023. Published by Elsevier B.V.

Uncontrolled inflammation leads to nonspecific destruction and remodeling of tissues and can contribute to many human pathologies, including pulmonary diseases. Stimulation of inflammatory resolution is considered an important process that protects against the progression of chronic inflammatory diseases. Resolvins generated from essential omega-3 polyunsaturated fatty acids have been demonstrated to be signaling molecules in inflammation with important pro-resolving and anti-inflammatory capabilities. By binding to specific receptors, resolvins can modulate inflammatory processes such as neutrophil migration, macrophage phagocytosis and the presence of pro-inflammatory mediators to reduce inflammatory pathologies. The discovery of these pro-resolving mediators has led to a shift in drug research from suppressing pro-inflammatory molecules to investigating compounds that promote resolution to treat inflammation. The exploration of inflammatory resolution also provided the opportunity to further understand the pathophysiology of pulmonary diseases. Alterations of resolution are now linked to both the development and exacerbation of diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, acute respiratory distress syndrome, cancer and COVID-19. These findings have resulted in the rise of novel design and testing of innovative resolution-based therapeutics to treat diseases. Hence, this paper reviews the generation and mechanistic actions of resolvins and investigates their role and therapeutic potential in several pulmonary diseases that may benefit from resolution-based pharmaceuticals.Copyright © 2023. Published by Elsevier B.V.